Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple... (rscheringpharma.de . Forward-Looking...)

HOME >> MEDICINE >> TECHNOLOGY

Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis

Date:9/26/2007

rscheringpharma.de .

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the initiation of clinical trials, regulatory plans and expected timelines for alemtuzumab, including the initiation of a second Phase 3 trial in MS patients and the timing thereof, the timing of obtaining clinical trial data, enrollment in clinical trials and the ability to manage patient safety. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: that final results of the clinical trial demonstrate safety and efficacy comparable to the interim data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements

Genzyme(R), Campath(R), and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved. Rebif(R) is a registered trademark of EMD Serono, Inc.<
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Accuray Incorporated ... the publication of study results involving hundreds of ... Radiosurgery System, the most widely used form of ... followed 304 patients for a median of 5 ... found that 97 percent of patients with low-risk ...

(Date:5/21/2013)... Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...

Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2

[0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment [0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference

... N.J., Dec. 15 Synvista Therapeutics, Inc. (NYSE ... dosed the first patient in a 30-patient Phase 2 ... patients with psoriasis. The trial is planned to be ... assess the efficacy of topical SYI-2074, applied twice daily, ...

... DIEGO, Dec. 14 bioTheranostics, a bioMerieux company,that ... in,oncology, reported today findings from three studies using ... of disease recurrence in,individual patients. Data from the ... Breast Cancer Symposium (SABCS). , ...

Cached Medicine Technology:Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 2 Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...

(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...

(Date:5/21/2013)... recently published in the New England Journal of ... the University of Colorado School of Medicine finds that ... be used to identify individuals at risk for this ... common variant of the gene for mucin-5B, a protein ... the bronchial tubes. While this variant of the MUC5B ...

Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Researchers find genetic risk factor for pulmonary fibrosis

... ... ... ... ...

... ... motorist and developed tinnitus, or severe ringing in her ears; she was granted compensation for ... ... carrier represented by East Tennessee attorney Brack Terry of Terry, Terry & Stapleton ...

... ... than £200 this month because of the cold snap. After one of the coldest Januarys in ... £226 – a £70 hike. , ... February 19, 2010 -- Britons are facing record energy bills of more than £200 this month ...

... Contrast-enhanced magnetic resonance imaging (MRI) may help physicians differentiate ... and wrist enabling more targeted therapies unique to each ... of the American Journal of Roentgenology . Contrast-enhanced ... internal bodily structures. Rheumatoid ...

... ... ... ... ...

MDS Announces Substantial Issuer Bid East Tennessee Attorney Brack Terry Obtains $120,000 Jury Award For Injured Mail Carrier It's Snow Joke as UK Gas and Electricity Bills Hit Record Highs -- Energyhelpline Calls for “Significant” Price Cuts Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis FDA Cancer Drug Approval Rate Highlighted in JNCI 'The Dance' Fundraising Event on February 25th Will Feature Belladiva Show Band; Silent Auction Items Include a Two-Week Condo Stay in New Zealand

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Chlamydia pneumoniae Antibodies, IgG & IgM by ELISA Chlamydia Group Antibody, Screen Chimerism, Recipient Pre-Transplant Chenodeoxycholic Acid